Ian F Tannock

发表

Tiffany Shao, Lisa Wang, Arnoud J Templeton, 2014, Journal of the National Cancer Institute.

Cognitive impairment associated with chemotherapy for cancer: report of a workshop.

Ian F Tannock, I. Tannock, P. Ganz, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of Molecular Biomarkers to Quantify the Spatial Distribution of Effects of Anticancer Drugs in Solid Tumors

Ian F Tannock, I. Tannock, Krupa J. Patel, 2013, Molecular Cancer Therapeutics.

Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings.

Ian F Tannock, Melania Pintilie, I. Tannock, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

When are "positive" clinical trials in oncology truly positive?

Ian F Tannock, I. Tannock, A. Ocaña, 2011, Journal of the National Cancer Institute.

Outcomes and endpoints in cancer trials: bridging the divide.

Katherine Karakasis, Deborah Collyar, Ian F Tannock, 2015, The Lancet. Oncology.

The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs.

Tiffany Shao, Ian F Tannock, Saroj Niraula, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.

Susan Halabi, Ian F Tannock, Ian M Thompson, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Factors associated with failure to publish large randomized trials presented at an oncology meeting.

Ian F Tannock, Melania Pintilie, I. Tannock, 2003, JAMA.

Enhanced drug delivery in rabbit VX2 tumours using thermosensitive liposomes and MRI-controlled focused ultrasound hyperthermia

Rajiv Chopra, Kullervo Hynynen, Ian F Tannock, 2012, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors

Lothar Lilge, Augusto Rendon, Ian F Tannock, 2005, Clinical Cancer Research.

The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors

Ian F Tannock, I. Tannock, Krupa J. Patel, 2009, BMC Cancer.

Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis.

Ben Tran, Arnoud J Templeton, Ian F Tannock, 2014, Journal of the National Cancer Institute.

Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy.

Ian F Tannock, I. Tannock, M. Egorin, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

The association between radiographic response and overall survival in men with metastatic castration‐resistant prostate cancer receiving chemotherapy

Gregory R Pond, Ian F Tannock, Andrew J Armstrong, 2011, Cancer.

The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors

Ian F Tannock, I. Tannock, Carol M Lee, 2010, BMC Cancer.

Potential drug interactions and duplicate prescriptions among cancer patients.

Lisa Wang, Ian F Tannock, I. Tannock, 2007, Journal of the National Cancer Institute.

Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials.

Lisa Wang, Ian F Tannock, I. Tannock, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Delivering affordable cancer care in high-income countries.

Karol Sikora, Peter Boyle, Paul Catchpole, 2011, The Lancet. Oncology.

Honorary and ghost authorship in reports of randomised clinical trials in oncology.

Arnoud J Templeton, Ian F Tannock, An-Wen Chan, 2016, European journal of cancer.

Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer.

Mark Clemons, Ian F Tannock, Andreas Laupacis, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis.

Ian F Tannock, I. Tannock, Joseph C Del Paggio, 2019, The Lancet. Oncology.